Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Jul
11
Today In Oncology
ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers
FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer
Long-Term Overall Survival With Addition of SBRT to Abiraterone Acetate and ADT in Oligometastatic Castration-Resistant Prostate Cancer
FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo